Mechanisms of tumor-related brain edema.
暂无分享,去创建一个
[1] Christopher Nimsky,et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. , 2006, Radiology.
[2] Thomas H. Mareci,et al. Computational Model of Interstitial Transport in the Spinal Cord using Diffusion Tensor Imaging , 2006, Annals of Biomedical Engineering.
[3] W. Hall,et al. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. , 2006, Neurosurgical focus.
[4] M. Bastin,et al. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. , 2006, AJNR. American journal of neuroradiology.
[5] C. Bokemeyer,et al. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416 , 2006, Leukemia & lymphoma.
[6] E. Oldfield,et al. A reassessment of vascular endothelial growth factor in central nervous system pathology. , 2005, Journal of neurosurgery.
[7] J. Bussink,et al. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. , 2005, International journal of radiation oncology, biology, physics.
[8] Yukihiko Fujii,et al. Diffusion tensor analysis of peritumoral edema using lambda chart analysis indicative of the heterogeneity of the microstructure within edema. , 2005, Journal of neurosurgery.
[9] J. Abbruzzese,et al. Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity , 2004, Cancer Research.
[10] E. Anaissie,et al. Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma , 2004, Clinical Cancer Research.
[11] N. Nathoo,et al. The eicosanoid cascade: possible role in gliomas and meningiomas , 2003, Journal of clinical pathology.
[12] M. Lauritzen,et al. Nitric oxide synthase expression and enzymatic activity in human brain tumors. , 2003, Clinical neuropathology.
[13] F. Cavalli,et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.
[14] Harumi Itoh,et al. Peritumoral brain edema in intracranial meningiomas evaluated by dynamic perfusion-weighted MR imaging: a preliminary study , 2003, European Radiology.
[15] D. Resnick,et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] Mark E Bastin,et al. Measurements of water diffusion and T1 values in peritumoural oedematous brain , 2002, Neuroreport.
[17] V. Glauche,et al. Correlation of Apparent Diffusion Coefficient and Computed Tomography Density in Acute Ischemic Stroke , 2002, Stroke.
[18] D. Davies,et al. Blood–brain barrier breakdown in septic encephalopathy and brain tumours * , 2002, Journal of anatomy.
[19] M. Papadopoulos,et al. Aquaporin-4 expression is increased in oedematous human brain tumours , 2002, Journal of neurology, neurosurgery, and psychiatry.
[20] M. Papadopoulos,et al. Occludin expression in microvessels of neoplastic and non‐neoplastic human brain , 2001, Neuropathology and applied neurobiology.
[21] T. Kuno,et al. Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. , 2001, The Kobe journal of medical sciences.
[22] K. Kono,et al. The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.
[23] J. Dichgans,et al. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15 , 2001, Neurology.
[24] M. C. Papadopoulos, S. Saadoun, D. C. Davies, B. A. B. Emerging molecular mechanisms of brain tumour oedema , 2001 .
[25] K. Plate,et al. VEGF in Brain Tumors , 2000, Journal of Neuro-Oncology.
[26] S. Liebner,et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme , 2000, Acta Neuropathologica.
[27] U. Bode,et al. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. , 2000, Klinische Padiatrie.
[28] S. Orrenius,et al. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells , 2000, Neuroscience.
[29] M. Delgado,et al. Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. , 1999, Journal of neurosurgery.
[30] W. Mayhan. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. , 1999, American journal of physiology. Cell physiology.
[31] K. Plate,et al. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. , 1999, Neurosurgery.
[32] Machein,et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells , 1999, Neuropathology and applied neurobiology.
[33] B. Rosen,et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. , 1999, Journal of neurosurgery.
[34] C. Andersen. The effect of glucocorticoids in the normal cerebral hemisphere of brain tumour patients , 1998, Acta neurologica Scandinavica.
[35] W. Cavenee,et al. Expression of vascular endothelial growth factor in human brain tumors , 1998, Acta Neuropathologica.
[36] E. Dejana,et al. Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration , 1998, The Journal of cell biology.
[37] Kazushi Fujimoto,et al. Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin , 1998, The Journal of cell biology.
[38] Y. Hirashima,et al. Platelet-activating factor and edema surrounding meningiomas. , 1998, Journal of Neurosurgery.
[39] V. Speirs,et al. Constitutive co‐expression of estrogen and progesterone receptor mRNA in human meningiomas by RT‐PCR and response of in vitro cell cultures to steroid hormones , 1997, International journal of cancer.
[40] S. Leung,et al. Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. , 1997, The American journal of surgical pathology.
[41] L. Rubin,et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. , 1997, Journal of cell science.
[42] C. Palmer,et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. , 1997, Neurosurgery.
[43] A. Guha,et al. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. , 1997, Neurosurgery.
[44] G. Palade,et al. Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.
[45] A. von Deimling,et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors , 1997, Acta Neuropathologica.
[46] P. Agre,et al. Specialized Membrane Domains for Water Transport in Glial Cells: High-Resolution Immunogold Cytochemistry of Aquaporin-4 in Rat Brain , 1997, The Journal of Neuroscience.
[47] S. Kalkanis,et al. Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. , 1996, Journal of neurosurgery.
[48] E. Papavassiliou,et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. , 1996, The Journal of clinical investigation.
[49] D. Mukhopadhyay,et al. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.
[50] T. Shono,et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. , 1995, Cancer research.
[51] G. Criscuolo,et al. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. , 1994, Journal of neurosurgery.
[52] T. Kawanami,et al. Electron microscopy of the blood‐brain barrier in disease , 1994, Microscopy research and technique.
[53] M. Itoh,et al. Occludin: a novel integral membrane protein localizing at tight junctions , 1993, The Journal of cell biology.
[54] Criscuolo Gr. The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. , 1993 .
[55] A. Ullrich,et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.
[56] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[57] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[58] H Ueno,et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.
[59] D. Connolly. Vascular permeability factor: A unique regulator of blood vessel function , 1991, Journal of cellular biochemistry.
[60] G. Butti,et al. A study on the biological behavior of human brain tumors Part I. Arachidonic acid metabolism and DNA content , 1991, Journal of Neuro-Oncology.
[61] P. McL. Black,et al. Human meningiomas co‐express platelet‐derived growth factor (pdgf) and pdgf‐receptor genes and their protein products , 1990, International journal of cancer.
[62] J. Posner,et al. Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma , 1990, Journal of Neuro-Oncology.
[63] H. Tenjin,et al. Metabolic and hemodynamic aspects of peritumoral low-density areas in human brain tumor. , 1990, Neurosurgery.
[64] E. Oldfield,et al. Cytosolic calcium changes in endothelial cells induced by a protein product of human gliomas containing vascular permeability factor activity. , 1989, Journal of neurosurgery.
[65] K. Go,et al. Peritumoral brain edema associated with meningiomas. , 1988, Neurosurgery.
[66] C C Chang,et al. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. , 1988, Journal of neurosurgery.
[67] J. Bruce,et al. Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. , 1987, Journal of neurosurgery.
[68] P. Stewart,et al. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. , 1987, Journal of neurosurgery.
[69] K. Black,et al. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans , 1986, Annals of neurology.
[70] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[71] D. Long,et al. Capillary ultrastructure in human metastatic brain tumors. , 1979, Journal of neurosurgery.
[72] H. Reulen,et al. Clearance of edema fluid into cerebrospinal fluid. A mechanism for resolution of vasogenic brain edema. , 1978, Journal of neurosurgery.
[73] D. Long. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. , 1970, Journal of neurosurgery.
[74] P. Bucy,et al. The treatment of glioblastoma multiforme of the brain. , 1967, Journal of neurosurgery.
[75] N. Ruderman,et al. Use of glucocorticoids in the palliative treatment of metastatic brain tumors , 1965, Cancer.
[76] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[77] W. Hall,et al. Convection-enhanced delivery: targeted toxin treatment of malignant glioma. , 2006, Neurosurgical focus.
[78] T. Schallert,et al. Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models. , 2005, Acta neurochirurgica. Supplement.
[79] K. Voigt,et al. Peritumoural brain oedema in intracranial meningiomas: Influence of tumour size, location and histology , 2005, Acta Neurochirurgica.
[80] H. Reulen,et al. Formation and propagation of brain oedema fluid around human brain metastases. A CT study , 2005, Acta Neurochirurgica.
[81] S. Shibata. Ultrastructure of capillary walls in human brain tumors , 2004, Acta Neuropathologica.
[82] R. Tanaka,et al. Magnetic resonance imaging and histopathology of cerebral gliomas , 2004, Neuroradiology.
[83] P. Stewart,et al. A quantitative study of blood-brain barrier permeability ultrastructure in a new rat glioma model , 2004, Acta Neuropathologica.
[84] M. van Lookeren Campagne,et al. Correlation of apparent diffusion coefficient and computed tomography density in acute ischemic stroke. , 2003, Stroke.
[85] K. Carson,et al. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. , 2002, Neuro-oncology.
[86] M. Papadopoulos,et al. Emerging molecular mechanisms of brain tumour oedema. , 2001, British journal of neurosurgery.
[87] R. Bullock,et al. Distinguishing between cellular and vasogenic edema in head injured patients with focal lesions using magnetic resonance imaging. , 2000, Acta neurochirurgica. Supplement.
[88] S. Liebner,et al. Liebner, S. et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 100, 323-331 , 2000 .
[89] T. Hander,et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[90] R. Blasberg,et al. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. , 1998, In vivo.
[91] E. Uhl,et al. Quantitative analysis of brain edema resolution into the cerebral ventricles and subarachnoid space. , 1997, Acta neurochirurgica. Supplement.
[92] H. Reulen,et al. Formation and resolution of human peritumoral brain edema. , 1994, Acta neurochirurgica. Supplementum.
[93] M. Yamamoto,et al. Peritumoral brain edema and cortical damage by meningioma. , 1994, Acta neurochirurgica. Supplementum.
[94] G. Criscuolo,et al. The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. , 1993, The Yale journal of biology and medicine.
[95] W. Reinhold,et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.
[96] H. Reulen,et al. A computed tomography study on formation, propagation, and resolution of edema fluid in metastatic brain tumors. , 1990, Advances in neurology.
[97] R. Aaslid,et al. Fluid flow rates in human peritumoural oedema. , 1990, Acta neurochirurgica. Supplementum.
[98] H. Reulen,et al. Peritumoral brain edema. A keynote address. , 1990, Advances in neurology.
[99] H. Reulen,et al. Clearance of edema fluid into cerebrospinal fluid , 1983 .
[100] A. Marmarou,et al. Biomechanics of brain edema and effects on local cerebral blood flow. , 1980, Advances in neurology.
[101] H. Reulen,et al. Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. , 1977, Journal of neurosurgery.
[102] I. Klatzo,et al. Presidental address. Neuropathological aspects of brain edema. , 1967, Journal of neuropathology and experimental neurology.